Syneos Health (SYNH)
(Delayed Data from NSDQ)
$37.58 USD
-0.35 (-0.92%)
Updated Feb 6, 2023 04:00 PM ET
After-Market: $37.59 +0.01 (0.03%) 7:58 PM ET
5-Strong Sell of 5 5
A Value D Growth D Momentum C VGM
Company Summary
Morrisville, NC based Syneos Health, Inc. is a key global biopharmaceutical solutions company offering a broad range of clinical and commercial facilities. The company majorly serves customers in the biopharmaceutical, biotechnology and medical device industries. Through its Contract Research Organization (CRO) and Contract Commercial Organization (CCO), it provides integrated and self-contained biopharmaceutical product development solutions varying from Early Phase (Phase I) clinical trials to complete commercialization of biopharmaceutical products.
Although incorporated as INC Research Holdings in August 2010, the company changed its name to Syneos Health after merging with inVentiv Health in 2017. ...
Company Summary
Morrisville, NC based Syneos Health, Inc. is a key global biopharmaceutical solutions company offering a broad range of clinical and commercial facilities. The company majorly serves customers in the biopharmaceutical, biotechnology and medical device industries. Through its Contract Research Organization (CRO) and Contract Commercial Organization (CCO), it provides integrated and self-contained biopharmaceutical product development solutions varying from Early Phase (Phase I) clinical trials to complete commercialization of biopharmaceutical products.
Although incorporated as INC Research Holdings in August 2010, the company changed its name to Syneos Health after merging with inVentiv Health in 2017. Syneos Health operates via two reportable arms. The details are as follows:
Clinical Solutions (76.9% of total revenues in 2021; constant exchange rate or CER growth was 18.8%): This segment offers a wide range of services supporting the entire clinical development process from Phase I to Phase IV. This business also provides services to various therapeutic areas with strength in complex therapeutic areas such as CNS and oncology. The portfolio includes:
Full service clinical development comprising services like patient recruitment and retention, site start-up and project management among others.
Strategic Resourcing.
Early Phase offering having a variety of services for Phase I to Phase IIA clinical trial conduct, bioanalytical analysis assay development and analysis, targeted translational science offerings, and clinical pharmacology services, including modeling and simulation.
Real World Evidence (RWE) and Late Phase services.
Syneos Health announced the buyout of clinical research home health services provider Illingworth Research Group in December 2020.
Commercial Solutions (23.1%; up 11.5%): This arm offers a wide range of complementary commercialization services, including specialized field teams and medication adherence services, communications solutions like advertising and public relations, and consulting services. Furthermore, it provides behavioral and patient insights that are used by the Clinical Solutions arm.
General Information
Syneos Health, Inc
1030 Sync Street
Morrisville, NC 27560
Phone: 919-876-9300
Fax: 919-876-9360
Web: http://www.syneoshealth.com
Email: investor.relations@syneoshealth.com
Industry | Medical Info Systems |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 12/31/2022 |
Exp Earnings Date | 2/16/2023 |
EPS Information
Current Quarter EPS Consensus Estimate | 1.21 |
Current Year EPS Consensus Estimate | 4.70 |
Estimated Long-Term EPS Growth Rate | NA |
Exp Earnings Date | 2/16/2023 |
Price and Volume Information
Zacks Rank | ![]() |
Yesterday's Close | 37.93 |
52 Week High | 92.58 |
52 Week Low | 22.89 |
Beta | 1.65 |
20 Day Moving Average | 1,513,895.38 |
Target Price Consensus | 42.45 |
4 Week | 8.59 |
12 Week | 10.42 |
YTD | 3.41 |
4 Week | 2.25 |
12 Week | 6.59 |
YTD | -4.02 |
Shares Outstanding (millions) | 102.90 |
Market Capitalization (millions) | 3,903.15 |
Short Ratio | NA |
Last Split Date | NA |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | 0.00 |
Change in Payout Ratio | 0.00 |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | 10.09 |
Trailing 12 Months | 7.63 |
PEG Ratio | NA |
vs. Previous Year | 0.89% |
vs. Previous Quarter | 0.00% |
vs. Previous Year | -0.89% |
vs. Previous Quarter | -1.80% |
Price/Book | 1.16 |
Price/Cash Flow | 6.03 |
Price / Sales | 0.72 |
12/31/22 | NA |
9/30/22 | 14.01 |
6/30/22 | 14.04 |
12/31/22 | NA |
9/30/22 | 5.69 |
6/30/22 | 5.69 |
12/31/22 | NA |
9/30/22 | 1.14 |
6/30/22 | 1.10 |
12/31/22 | NA |
9/30/22 | 1.14 |
6/30/22 | 1.10 |
12/31/22 | NA |
9/30/22 | 8.68 |
6/30/22 | 8.66 |
12/31/22 | NA |
9/30/22 | 5.31 |
6/30/22 | 5.13 |
12/31/22 | NA |
9/30/22 | 7.22 |
6/30/22 | 6.91 |
12/31/22 | NA |
9/30/22 | 32.67 |
6/30/22 | 32.43 |
12/31/22 | NA |
9/30/22 | NA |
6/30/22 | NA |
12/31/22 | NA |
9/30/22 | 0.84 |
6/30/22 | 0.86 |
12/31/22 | NA |
9/30/22 | 45.52 |
6/30/22 | 46.22 |